NATCO launches anti blood clot tablet Rivaroxaban in India

Natco Pharma Limited {NSE: NATCOPHARM; BSE: 524816) has announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto®, in the Indian market.

After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line wit h our Company's mission of affordable medicines accessible to all. NATCO has launched RPIGAT in four strengths - 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.948.45 as compared to the previous close of Rs. 946.55. The total number of shares traded during the day was 8573 in over 366 trades.

The stock hit an intraday high of Rs. 966.95 and intraday low of 945. The net turnover during the day was Rs. 8142391.

Source : Equity Bulls

Keywords